Dr. Bestvina on Challenges With Interpreting Molecular Reports in Lung Cancer


In Partnership With:

Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.

Christine Bestvina, MD, assistant professor of medicine, Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, discusses challenges with interpreting molecular reports in lung cancer.

Several challenges in receiving and interpreting molecular reports exist in the lung cancer paradigm, Bestvina explains. For example, the available molecular profiling platforms present the data differently. Therefore, it may not always be clear which mutations are being tested for, how the data are recorded, and how the data are reported, Bestvina says. Additionally, it is unclear for some platforms whether targets, TKIs, and other available agents are being weighed for potential actionability in the context of identified aberrations.

Moreover, as these molecular platforms are often based outside of an institution, the information generated is not always uploaded to electronic medical records (EMRs), which makes reporting the data in EMRs challenging for the clinician receiving the data, Bestvina concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD